A Phase I, Open-Label, Dose-Seeking Study of AZD2171 [cediranib] Given Daily Orally in Combination With Selected Standard Chemotherapy Regimens (CT) in Patients With Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer.

Trial Profile

A Phase I, Open-Label, Dose-Seeking Study of AZD2171 [cediranib] Given Daily Orally in Combination With Selected Standard Chemotherapy Regimens (CT) in Patients With Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Cediranib (Primary) ; Cisplatin; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin
  • Indications Colorectal cancer; Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 16 Mar 2010 Actual end date (1 Sep 2008) added as reported by ClinicalTrials.gov record.
    • 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top